Abstract

Previous reports have shown that during chronic inflammation, the tryptophan (TRP)-kynurenine (KYN) pathway plays a pivotal role in the onset of depression. The aim of this study was to investigate the characteristics of the serum TRP-KYN pathway metabolite profile in high-risk subjects of major depressive disorder (HRMDD) defined by depression scores. The concentrations of TRP-KYN pathway metabolites {TRP, KYN, 3-hydroxyanthranilic acid (3HAA), 3-hydroxykynurenine (3HK), kynurenic acid (KYNA) and anthranilic acid (AA)} were assessed in serum from HRMDD, chronic pain disorder patients and healthy controls. In serum from HRMDD, elevated levels of AA and decreased levels of TRP were observed, but the levels of other metabolites were not changed. Furthermore, the change in the AA2nd/AA1st ratio in subjects who progressed from a healthy state to a depressive state was correlated with an increase in the CES-D score. The level of IL-1 receptor antagonist (IL-1RA) was negatively correlated with that of AA. Interestingly, we confirmed AA as a possible biomarker for depression-related symptoms, since the metabolite profiles in the chronic pain disorder group and chronic unpredictable mild stress model mice were similar to those in the HRMDD. These results suggest that AA may be an effective marker for HRMDD.

Details

Title
Serum Metabolic Profiles of the Tryptophan-Kynurenine Pathway in the high risk subjects of major depressive disorder
Author
Sakurai Masashi 1 ; Yamamoto Yasuko 2 ; Kanayama Noriyo 1 ; Hasegawa Masaya 3 ; Mouri Akihiro 4   VIAFID ORCID Logo  ; Takemura Masao 5 ; Matsunami Hidetoshi 6 ; Miyauchi Tomoya 7   VIAFID ORCID Logo  ; Tokura Tatsuya 7 ; Kimura Hiroyuki 7 ; Ito Mikiko 8 ; Umemura Eri 8 ; (Boku) Aiji Sato 9 ; Nagashima Wataru 10 ; Tonoike Takashi 11 ; Kurita Kenichi 8 ; Ozaki Norio 7   VIAFID ORCID Logo  ; Nabeshima Toshitaka 12 ; Saito Kuniaki 13 

 Kyoto University, Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033) 
 Kyoto University, Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033); Fujita Health University Graduate School of Health Sciences, Department of Disease Control and Prevention, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X) 
 Fujita Health University Graduate School of Health Sciences, Department of Regulatory Science, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X) 
 Fujita Health University Graduate School of Health Sciences, Department of Regulatory Science, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X); Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan (GRID:grid.256115.4) 
 Fujita Health University Graduate School of Health Sciences, Department of Disease Control and Prevention, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X) 
 Matsunami Research Park, Gifu, Japan (GRID:grid.256115.4) 
 Nagoya University, Graduate School of Medicine, Department of Psychiatry, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X) 
 Aichi Gakuin University, Department of Oral and Maxillofacial, Surgery, School of Dentistry, Nagoya, Japan (GRID:grid.411253.0) (ISNI:0000 0001 2189 9594) 
 Aichi Gakuin, University, Department of Anesthesiology, Nagoya, Japan (GRID:grid.411253.0) (ISNI:0000 0001 2189 9594) 
10  Nagoya University, Graduate School of Medicine, Department of Psychopathology and Psychotherapy/Center for Student Counseling, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X) 
11  Aichi Gakuin University, Faculty of Psychological and Physical Sciences, Health Service Center, Nisshin, Japan (GRID:grid.411253.0) (ISNI:0000 0001 2189 9594) 
12  Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan (GRID:grid.27476.30); Fujita Health University Graduate School of Health Sciences, Advanced Diagnostic System Research Laboratory, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X) 
13  Kyoto University, Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033); Fujita Health University Graduate School of Health Sciences, Department of Disease Control and Prevention, Toyoake, Japan (GRID:grid.256115.4) (ISNI:0000 0004 1761 798X); Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan (GRID:grid.256115.4) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2352044152
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.